Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2026-04-21 Board/Management Inform…
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Appointment of Mr. Vinay Subramanian Commercial Head, Oncology
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior managerial personnel at GlaxoSmithKline Pharmaceuticals Limited. It references compliance with Regulation 30 of SEBI Listing Regulations, which pertains to disclosure of material events including changes in management. The content details the appointment of Mr. Vinay Subramanian to the senior management team, including his background and qualifications. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of management change, fitting the category of Board/Management Information (MANG). The document length is 3169 characters, which is typical for such announcements and not a full report or presentation.
2026-04-21 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related actions. The document is addressed to stock exchanges and is a formal attestation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is primarily a regulatory compliance certificate, which fits the category of Regulatory Filings (RNS) as per the certification rule and fallback category for such compliance documents.
2026-04-09 English
As per attachment
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related actions. The document is addressed to stock exchanges and is a formal attestation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 2668 characters, which is relatively short and consistent with a certification or regulatory filing. According to the rules, such officer certifications or compliance certificates should be classified as Regulatory Filings (RNS).
2026-04-09 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed report on the results of a postal ballot conducted by GlaxoSmithKline Pharmaceuticals Limited. It includes voting results, scrutinizer's report, and details about the resolutions passed, specifically the appointment of a director and a whole-time director & CFO. The document references compliance with the Companies Act, 2013, and SEBI regulations, and provides comprehensive voting data and the scrutinizer's certification of the voting process. This is not a simple announcement or notice but a full report on the voting results and scrutinizer's findings. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief announcement or a proxy solicitation but a full voting result report.
2026-04-08 English
As per attachment
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed communication from GlaxoSmithKline Pharmaceuticals Limited to stock exchanges regarding the results of a postal ballot. It includes voting results, scrutinizer's report, and details about the appointment of a director and a whole-time director & CFO. The document references compliance with the Companies Act, 2013, and SEBI regulations, and provides detailed voting statistics and the scrutinizer's certification of the voting process. The content is focused on the announcement of voting results from a shareholder postal ballot, not the notice of the meeting itself or proxy solicitation materials. It is not a full annual report, earnings release, or management discussion. The document is not a regulatory filing or a report publication announcement since it contains substantive voting results and scrutinizer's report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2026-04-08 English
As per attachment
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed communication from GlaxoSmithKline Pharmaceuticals Limited to stock exchanges regarding the results of a postal ballot. It includes voting results, scrutinizer's report, and details about the appointment of a director and a whole-time director & CFO. The document references compliance with the Companies Act, 2013, and SEBI regulations, and provides detailed voting statistics and the scrutinizer's certification of the voting process. This is not an announcement of a report publication but the actual detailed voting results and scrutinizer report. The content clearly pertains to the declaration of voting results from a shareholder postal ballot. Therefore, the document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA). The document length and detail confirm it is not a brief announcement or a proxy solicitation but the official voting results report.
2026-04-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.